2 active not recruiting, 1 recruiting, 1 unknown. 2 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Active not recruiting 1, Recruiting 1 |
| Phase 2 | 1 | Active not recruiting 1 |
Follow Locally Advanced Cholangiocarcinoma: new trials by email Literature Review of Locally Advanced Cholangiocarcinoma trials Research Report on Locally Advanced Cholangiocarcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or Metastatic Cholangiocarcinoma or Pancreatic Cancer Biopsy Procedure, Cisplatin, Computed Tomography - Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma | Phase 1 | Recruiting | Jonsson Comprehensive Cancer Center | 46 | 2026-05-29 | 2026-08-20 |
| Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma Biopsy, Biospecimen Collection, Computed Tomography - Locally Advanced Cholangiocarcinoma, Metastatic Cholangiocarcinoma | Phase 2 | Active not recruiting | University of Kansas Medical Center | 15 | 2024-02-01 | 2026-02-24 |
| Safety and Anti-Tumor Activity of TYRA-200 in Advanced Cholangiocarcinoma With Activating FGFR2 Gene Alterations Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles, Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles - Locally Advanced Cholangiocarcinoma, Intrahepatic Cholangiocarcinoma | Phase 1 | Active not recruiting | Tyra Biosciences, Inc | 40 | 2023-11-22 | 2026-10-14 |
| Clinical Feasibility of Nab-paclitaxel Plus Gemcitabine-cisplatin Chemotherapy in Locally Advanced Cholangiocarcinoma Locally Advanced Cholangiocarcinoma | Unknown | CHA University | 100 | 2023-03-20 | 2024-02-07 |
Cholangiocarcinoma (3) · Acrocephalosyndactylia (1) · Klatskin Tumor (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1)
Adenocarcinoma (3) · Carcinoma (3) · Neoplasms (3) · Neoplasms by Histologic Type (3) · Neoplasms, Glandular and Epithelial (3) · Bone Diseases (1) · Bone Diseases, Developmental (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · Craniofacial Abnormalities (1) · Craniosynostoses (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Dysostoses (1) · Endocrine Gland Neoplasms (1)
Biopsy (2) · Magnetic Resonance Spectroscopy (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Cisplatin (1) · Disulfides (1) · Fluorouracil (1) · Gemcitabine (1) · Immunoglobulin G (1) · Irinotecan (1) · Leucovorin (1) · Oxaliplatin (1) · Platinum (1) · Specimen Handling (1) · dehydroftorafur (1) · durvalumab (1)
CHA University (1) · Jonsson Comprehensive Cancer Center (1) · Tyra Biosciences, Inc (1) · University of Kansas Medical Center (1)
United States (3) · South Korea (1)
Doug Warner (1) · Hong Jae Chon, MD,PhD (1) · Lee S Rosen (1)
P30CA168524 (1)